This event has passed. View key highlights below.
At the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Xyzagen presented new research on behalf of Spring Discovery focused on the repurposing of disulfiram as a potential treatment for retinal disease. The meeting was held April 23–27, 2023, in New Orleans, Louisiana.
The presentation highlighted findings from SPR-397, a 0.25% ophthalmic solution developed from the FDA-approved drug disulfiram, and its potential to address inflammatory mechanisms underlying dry eye disease.
Scientific Focus
The study, titled “SPR-397, 0.25% Ophthalmic Solution May Break the Inflammatory Cycle of Dry Eye Disease,” explored a novel application of a well-characterized compound in an ophthalmic setting. The research demonstrated how targeted repurposing strategies may offer new therapeutic options for dry eye disease by interrupting key inflammatory pathways.
This work reflects the potential of leveraging known safety profiles while applying rigorous pharmacology and pharmacokinetic principles to new indications.
Executive Quote
“The ARVO Annual Meeting is an excellent venue for sharing our client’s vision research advancements,” said Christopher Crean, Founder and CEO of Xyzagen. “Our work on disulfiram underscores Xyzagen’s mission to support innovative strategies for repurposing known compounds to address complex diseases such as dry eye.”
Presentation Details
Poster Title: SPR-397, 0.25% Ophthalmic Solution May Break the Inflammatory Cycle of Dry Eye Disease
Session: Poster Session 710-B0381
Presentation Date: April 25, 2023
Authors: Christopher Crean, Angela Dixon, Wendy Cousin, Ransi Somaratne
Final Takeaways
This presentation highlights Xyzagen’s experience supporting ophthalmology programs through integrated clinical pharmacology and PK expertise, including the strategic repurposing of established compounds. By applying translational insight to ophthalmic drug development, Xyzagen helps sponsors evaluate new therapeutic opportunities with efficiency and confidence.
If you’re interested in how Xyzagen can support ophthalmology or ocular drug development programs—from repurposing strategies to translational PK—contact us today to learn more.
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine. Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
Media Contact:
Christopher Crean
Founder & CEO
Xyzagen, Inc.
Phone: 919-726-2072
Email: [email protected]
